Renishaw PLC
LSE:RSW
Renishaw PLC
Renishaw PLC began its journey in 1973, sparked by the innovative spirit of Sir David McMurtry and John Deer. Initially rooted in the creation of more precise measuring equipment, Renishaw has navigated technological mazes to become a global leader in measurement, healthcare, and manufacturing technologies. The spark that lit Renishaw’s torch was McMurtry's invention of the touch-trigger probe while working at Rolls-Royce, a defining moment that paved the way for the company’s focus on metrology: the science of measurement. Today, this niche expertise enables Renishaw to provide a multitude of industries—from aerospace to healthcare—with sophisticated solutions that enhance precision and efficiency across the globe.
Renishaw’s financial health flourishes through its diverse yet intricately connected product offerings. Core to its business model is metrology, where it sells advanced systems and products like coordinate measuring machines, machine tool probes, and software. These products are vital for manufacturing companies seeking to ensure higher quality control and production efficiencies. Beyond metrology, Renishaw dabbles in healthcare, particularly in dental and neurological fields, with its innovative 3D printing technologies and stereotactic neurosurgery tools that offer new vistas in patient care. The synergy between traditional precision measurement and cutting-edge innovation amplifies its market presence, thus securing Renishaw’s place in both established and emerging industries.
Renishaw PLC began its journey in 1973, sparked by the innovative spirit of Sir David McMurtry and John Deer. Initially rooted in the creation of more precise measuring equipment, Renishaw has navigated technological mazes to become a global leader in measurement, healthcare, and manufacturing technologies. The spark that lit Renishaw’s torch was McMurtry's invention of the touch-trigger probe while working at Rolls-Royce, a defining moment that paved the way for the company’s focus on metrology: the science of measurement. Today, this niche expertise enables Renishaw to provide a multitude of industries—from aerospace to healthcare—with sophisticated solutions that enhance precision and efficiency across the globe.
Renishaw’s financial health flourishes through its diverse yet intricately connected product offerings. Core to its business model is metrology, where it sells advanced systems and products like coordinate measuring machines, machine tool probes, and software. These products are vital for manufacturing companies seeking to ensure higher quality control and production efficiencies. Beyond metrology, Renishaw dabbles in healthcare, particularly in dental and neurological fields, with its innovative 3D printing technologies and stereotactic neurosurgery tools that offer new vistas in patient care. The synergy between traditional precision measurement and cutting-edge innovation amplifies its market presence, thus securing Renishaw’s place in both established and emerging industries.
Revenue Growth: Renishaw delivered record H1 revenue, up 7.1% reported and 11.5% at constant currency, with strong Q2 momentum.
Segment Performance: Growth was strong in the Americas and APAC, but EMEA remained soft, especially in the German machine tool market.
Margins Up: Operating margin improved by 0.6 percentage points to 15.7%, aided by cost reductions and despite significant currency headwinds.
Cost Actions: A GBP 20 million cost reduction program and the closure of the loss-making drug delivery business drove profit improvement.
Emerging Businesses: Fastest growth came from Specialized Technologies (over 25% at constant currency), especially Additive Manufacturing and defense-related demand.
Product Innovation: Management highlighted successful new product launches, including Equator-X, new laser encoders, and the LIBERTAS software for additive manufacturing.
Guidance Positive: Management expressed confidence in continued revenue and profit growth for the full year, maintaining a positive outlook.
Dividend Steady: Interim dividend held flat at 16.8p, prioritizing dividend cover and capital allocation discipline.
